Introduction
============

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by bradykinesia, muscular rigidity, and tremor ([@b42-ndt-3-145]). Among the three cardinal symptoms, bradykinesia is the most important and mainly contributes to the disability associated with PD progression. The term bradykinesia refers to the slowness and poverty of voluntary and involuntary movements characteristic of parkinsonism. Muscular rigidity, defined as the increased resistance of a joint to passive movements, only minimally contributes to the impairment experienced by parkinsonian patients. The subjective correlate of rigidity is a feeling of stiffness and reduced ability to relax limb and trunk muscles. Tremor is the most conspicuous of the cardinal symptoms of PD, and gave rise to the initial name of the disease, shaking palsy, by James Parkinson in 1817. Parkinsonian tremor usually occurs during rest, and typically affects the upper limbs, but may also occur in the legs and less frequently in the head. Although resting tremor is not necessarily disabling, many patients suffer considerably from it, not least because tremor stigmatizes them as parkinsonian subjects.

The cardinal motor symptoms of PD depend upon progressive degeneration of the dopamine-containing neurons in the substantia nigra *pars compacta* ([@b37-ndt-3-145]). The nigrostriatal dopaminergic damage can be monitored by functional neuroimaging techniques, such as positron emission tomography (PET) or single photon emission tomography (SPECT) ([@b29-ndt-3-145]). Such methods contributed to establish that approximately 50% reduction in dopaminergic nigrostriatal cells is required before clinical expression of the motor symptoms ([@b63-ndt-3-145]; [@b46-ndt-3-145]).

Therapy of PD is, at present, symptomatic, aimed at ameliorating clinical symptoms ([@b58-ndt-3-145]). Available drugs include levodopa, dopamine receptor agonists, anticholinergics, and antiglutamatergics. A more complete therapeutic approach to PD, however, should also be aimed at neuroprotection (slowing the progression of neuronal degeneration), neurorescue (normalizing injured neurons that are not yet dead), and neurorestoration (increasing the number of neurons by directly implanting new ones or causing existing cells to divide). Although functional neuroimaging data support the potential neuroprotective effect of some dopamine receptor agonists in PD ([@b55-ndt-3-145]; [@b76-ndt-3-145]), the development of effective neuroprotective strategies is still limited by difficulties in making the correct diagnosis early during the course of illness.

Recent neuropathological data indicate that the pathological landmark of PD, the Lewy bodies, can be identified in several neuronal populations other than the dopaminergic mesencephalic ones ([@b14-ndt-3-145]). Following the ascending gradient of neuronal involvement throughout disease progression, 6 neuropathological stages of PD have been identified ([@b15-ndt-3-145]): in stages 1 and 2, defined as "presymptomatic stages", the Lewy bodies are confined to the anterior olfactory nucleus, olfactory bulb, dorsal motor nucleus of the glossopharyngeal and vagal nerves, locus coe-ruleus, and reticular formation. In stages 3 and 4 ("intermediate stages"), the neuropathological damage extends to the substantia nigra pars compacta, other mesencephalic nuclei, the prosencephalon and meso-allocortical regions; during these stages, the motor symptoms develop and progressively worsen. Eventually, in stages 5 and 6 ("advanced stage" of PD), neocortical, prefrontal, and associative cortices are pathologically involved; in these latter stages, severe motor disturbances are accompanied by cognitive and behavioral symptoms. As a result of these neuropathological findings, the original description of PD as due to the selective damage of dopaminergic neurons in the mesencephalon should be updated into the concept of a severe multisystemic neurodegenerative disorder, whose clinical symptoms reflect the progression of the pathological involvement from the medulla oblongata to neocortical areas.

One of the most intriguing aspects of the studies by [@b14-ndt-3-145], [@b15-ndt-3-145] is that the neuropathological alterations outside the substantia nigra are soundly correlated with some non-motor symptoms of PD. Thus, the identification of early non-motor symptoms of PD and the application of instrumental methodologies may contribute to making the correct diagnosis of PD during the pre-motor stages. To this end, the identification of genetic mutations responsible for hereditary forms of PD ([@b13-ndt-3-145]) plays a crucial role, as it allows study of mutation carriers before the onset of the motor symptoms.

Based on the localization of Lewy bodies during the pre-symptomatic stages of PD, the following non-motor symptoms may play a role as prodromal markers of the disease:

-   Autonomic disturbances

-   Olfactory dysfunctions

-   Psychiatric symptoms

-   Sleep disorders, in particular REM sleep behavior disorder (RBD)

Prodromal non-motor symptoms of PD
==================================

Autonomic disturbances
----------------------

Dysautonomia is a key characteristic of multiple system atrophy (MSA), but occurs with varying severity in PD (Chauduri 2001). The pathophysiology of dysautonomia in PD is complex and includes degeneration and dysfunction of autonomic nuclei such as the dorsal vagal nucleus, the nucleus ambiguus, and other medullary nuclei which exert differential control on the sympathetic preganglionic neurons via descending pathways ([@b9-ndt-3-145]). Additionally, degeneration of cholinergic, monoaminergic and serotonergic nuclei may cause abnormalities of modulatory effects within the central autonomic network ([@b9-ndt-3-145]).

Subtle autonomic disturbances that can at least partly be related to the degeneration of the vagal nerve are an early and frequent sign in PD ([@b48-ndt-3-145]). Almost all PD patients suffer from constipation ([@b45-ndt-3-145]). An epidemiological study of 6790 men followed prospectively in the Honolulu Heart Program showed that men with less than one bowel movement per day had a 4.5-fold excess risk of developing PD versus men with more than two bowel movements per day ([@b1-ndt-3-145]). These observations are compatible with the view that constipation is part of an early PD process. Nevertheless, such gastrointestinal symptoms are poorly specific in nature, besides being often aggravated by drugs such as tricyclic antidepressants.

Although troublesome dysautonomia is only thought to complicate advanced disease, cardiac meta-iodobenzylguanidine (MIGB) imaging challenges this view by showing early cardiac sympathetic denervation in PD and not multiple system atrophy ([@b31-ndt-3-145]). Cardiac sympathetic denervation has also been linked to genetic forms of PD with alpha-synuclein mutations ([@b66-ndt-3-145]).

Autonomic function in PD can be objectively assessed by several validated methods, including quantitative sudomotor axon reflex test, urodynamic studies, defecating proctography, tilt test, sympathetic skin response, and pupil function test with pilocarpine or phenylepinephrine ([@b5-ndt-3-145]). In cases where distinction from MSA is needed, tests such as urethral sphincter electromyography, plasma norepinephrine concentration in response to head-up tilting, and clonidine-induced growth hormone challenge test may be useful ([@b5-ndt-3-145]).

Olfactory dysfunctions
----------------------

Olfactory disorders occur frequently in PD. More than 50% of patients suffering PD experience anosmia, 35% of patients have severe hyposmia and 14% of patients moderate hyposmia ([@b33-ndt-3-145]; [@b49-ndt-3-145]). The olfactory deficit in PD shows above all an increase of olfactory threshold, and minor alterations of identificative and discriminative functions ([@b69-ndt-3-145]). The olfactory dysfunctions in PD depend on damage of the dopaminergic neurons in the olfactory bulb and olfactory nuclei. However, olfactory deficit is not responsive to antiparkinsonian drugs and is not related to the severity of motor symptoms ([@b25-ndt-3-145], [@b26-ndt-3-145]; [@b69-ndt-3-145]). Such apparent discrepancy may depend on the precocious damage of the olfactory system in PD, which makes olfactory dysfunction already advanced at the time of onset of motor symptoms, ie, when the clinical diagnosis of PD is made.

Several lines of evidence suggest that olfactory dysfunction is a potential pre-motor marker of PD. [@b4-ndt-3-145] first suggested the association between olfactory dysfunction and the development of PD. Subsequently, [@b25-ndt-3-145], [@b26-ndt-3-145], [@b49-ndt-3-145], and [@b57-ndt-3-145] indicated hyposmia as a prodromal marker of the disease. Studies on healthy first degree relatives of parkinsonians in families with hereditary or sporadic PD confirmed that olfactory dysfunctions may be a pre-motor marker of the disease: indeed, olfactory dysfunctions have been identified in 41% of healthy subjects in families with autosomal dominant PD ([@b47-ndt-3-145]), and other studies reported that olfactory dysfunction is associated with an increased risk of developing PD among first degree relatives of sporadic PD patients ([@b77-ndt-3-145]; [@b57-ndt-3-145]).

Further data suggest that olfactory function may be a potentially useful test also to distinguish PD from atypical parkinsonism. In a controlled but unblinded study using the University of Pennsylvania Smell Identification Test (UP-SIT), patients with progressive supranuclear palsy (PSP) had similar olfaction to normal controls, but differed from patients with PD ([@b27-ndt-3-145]). Using the same method, [@b75-ndt-3-145] reported normal olfactory scores in PSP and corticobasal ganglionic degeneration, and significantly worse scores in PD patients. Interestingly, patients with MSA scored worse than control, but significantly better than PD. Finally, in a prospective study using the "sniffing sticks", all PD patients had moderate to severe hyposmia or anosmia, while patients with other parkinsonisms or essential tremor (ET) had normal or only mild to moderate hyposmia ([@b49-ndt-3-145]).

Psychiatric symptoms
--------------------

Depression is extremely frequent in PD, occurring in up to 45% of cases ([@b18-ndt-3-145]). Depression is not necessarily related to the severity of motor symptoms of PD, and is often misdiagnosed since hypomimia and reduction of voluntary movements are common to both PD and pure depression. Therefore, the identification of depression in PD patients is essentially based upon subjective perception of depressive symptoms such as feeling of incapability, reduced reaction to emotional stimuli, and inability to experience pleasure from things and events (anhedonia).

The pathophysiology of depression in PD is rather complex, being related to damage of the noradrenergic, serotonergic and dopaminergic pathways in the brain ([@b24-ndt-3-145]; [@b59-ndt-3-145]). Indeed, the pattern of depressive symptoms in PD appears different from that of pure depression. Typical signs of depression in PD are a raised degree of dysphoria and irritability, pessimism about future, with low levels of inadequacy and sense of guilt ([@b59-ndt-3-145]).

Interest in depression in PD has increased recently not only for the need of pharmacological treatment, but also for its potential role as a pre-motor marker of the disease. In a case-control study, the occurrence of depression in the last 5 years was significantly linked to future development of motor symptoms of PD ([@b65-ndt-3-145]). Similar findings were drawn from a cohort study ([@b52-ndt-3-145]). A longitudinal study showed the increased risk of developing PD in depressed subjects as compared to not depressed ones ([@b62-ndt-3-145]). Finally, [@b43-ndt-3-145] reported that patients with PD more often had a primary (preceding the onset of PD) diagnosis of single phobia and a secondary atypical depression than did those with dystonia. In conclusion, although the pathophysiological and neurochemical features linking the two disorders are not completely known, the correlation between depression and PD is consolidated to such a point that depression can be considered a non-motor sign of PD, potentially useful in the pre-motor stages of the disease.

Anxiety is also common in PD, and may represent a pre-motor risk factor ([@b65-ndt-3-145]; [@b74-ndt-3-145]). Anxiety can be present as panic attacks, phobias, or generalized anxiety disorder, and can be related to drug-induced motor fluctuations in PD.

Sleep disorders
---------------

Virtually all PD patients develop sleep disruption, and there is evidence that the process usually begins early in the course of the disease ([@b23-ndt-3-145]). Sleep disturbance in PD has a multifactorial etiology, but pathological degeneration of central sleep regulation centers in the brainstem and thalamocortical pathways is probably important ([@b60-ndt-3-145]).

RBD is a specific disorder during the REM phase of sleep ([@b30-ndt-3-145]), characterized by sudden motor-behavioral episodes of violent nature, associated with attitudes of defense from a threat and vocalizations. The oneiric experience lived by the patient, which almost always has a threatening and unpleasant content, is closely reflected in his movements. Sometimes, the motor features are directed towards others.

Sleep disorders, and RBD in particular, are often seen in synucleinopathies such as PD, MSA, and diffuse Lewy body dementia (Shenk et al 1996; [@b53-ndt-3-145]). The prevalence of RBD in PD is estimated at between 15% and 33%, increasing to 58% if one takes into account subclinical RBD (Shenk et al 1996). Some reports show that RBD evolves together with the motor symptoms in PD, and also that RBD can precede the onset of motor symptoms. In this respect, two epidemiological studies proved that PD develops in 40%--50% of subjects suffering RBD ([@b61-ndt-3-145]; [@b53-ndt-3-145]). Moreover, the evidence of dopaminergic nigrostriatal damage in RBD, as measured by SPECT ([@b28-ndt-3-145]), suggests that RBD can represent an early symptom of PD, in particular when associated with olfactory dysfunction ([@b68-ndt-3-145]).

In addition to RBD, recent data suggest that excessive daytime sleepiness may also be a pre-motor marker of PD ([@b2-ndt-3-145]). It is important to recognize excessive daytime sleepiness, as it can substantially affect quality of life in PD. A combination of the disease process, the effect of nocturnal sleep deprivation, and antiparkinsonian drugs is probably causative and, in some patients, excessive daytime sleepiness has been linked to the development of sudden-onset sleep ([@b70-ndt-3-145]).

Biomarkers
==========

Neuropathological and clinical findings suggest, therefore, that PD is a multisystemic neurodegenerative disorder, and that not-motor symptoms may play a role not only in determining functional impairment, but also as early markers of the disease.

Although autonomic or olfactory dysfunctions, psychiatric symptoms and sleep disorders may represent prodromal markers of PD, it should be pointed out that none of these symptoms is specific to PD, since they all may occur as idiopathic disorders or during the course of other neurodegenerative diseases, such as Alzheimer's dementia ([@b38-ndt-3-145]; [@b36-ndt-3-145]; [@b16-ndt-3-145]; [@b34-ndt-3-145]). Thus, the identification of pre-motor signs in subjects at risk to develop PD needs to be associated with instrumental evidence of the damage to dopamine nigrostriatal pathway in order to make a correct presymptomatic diagnosis of the disease.

Functional neuroimaging
-----------------------

One of the goals of functional neuroimaging is the presymptomatic detection of patients, and there are now several publications to suggest this may be possible. For example, patients with hemi-Parkinson's disease showed reduced uptake of the ipsilateral as well as the expected contralateral side ([@b63-ndt-3-145]), twin studies have shown a dopaminergic deficit in asymptomatic twins of patients with PD ([@b17-ndt-3-145]; [@b35-ndt-3-145]; [@b44-ndt-3-145]), and dopaminergic dysfunction has been shown in people after taking 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine prior to the onset of motor symptoms ([@b19-ndt-3-145]). However, one unresolved issue with these studies is whether subjects with preclinical imaging abnormalities actually go on to develop PD, although data from one of the twin studies suggest that at least some do ([@b56-ndt-3-145]). Moreover, the high cost of these methodologies prevents their application to the screening on wide populations of at risk subjects. Thus, interest is growing in the characterization of other tools that can contribute to the early identification of the damage of dopaminergic neurons in PD.

Transcranial sonography
-----------------------

In 1995, Becker et al reported a highly characteristic enlargement of echogenic signal (hyperechogenicity) of the substantia nigra in idiopathic PD. Since then, a number of studies has been performed indicating that this method is a valuable tool for the differential diagnosis of PD, which even allows the identification of subjects at risk for nigrostriatal dysfunction. Evidence that this method is indeed valid comes from the following findings: (i) several groups independently demonstrated that the hyperechogenicity of the substantia nigra is a characteristic ultrasound finding in more than 90% of PD patients ([@b11-ndt-3-145]; [@b71-ndt-3-145]; [@b78-ndt-3-145]); (ii) the reproducibility is high, with very low inter rater variation ([@b10-ndt-3-145]; [@b11-ndt-3-145]); (iii) prospective studies with two independent sonographers/raters, of whom at least one was blinded to the clinical data of patients, indicate a high predictive value of an association between hyperechogenicity of the substantia nigra and nigrostriatal impairment ([@b10-ndt-3-145]; [@b72-ndt-3-145]); (iv) substantia nigra hyperechogenicity indeed reflects an alteration linked to nigrostriatal impairment, since it is larger contralateral to the clinically more affected side ([@b11-ndt-3-145]), it is present in PD but not ET, and only very rarely in atypical parkinsonian syndromes, such as striatonigral degeneration and PSP ([@b72-ndt-3-145]; [@b51-ndt-3-145]; [@b8-ndt-3-145]), and can be visualized in healthy subjects showing mild impairment of the nigrostriatal system ([@b10-ndt-3-145]); (v) lastly, substantia nigra hyperechogenicity appears associated with the reduction of striatal ^18^F-dopa uptake in healthy subjects ([@b10-ndt-3-145], [@b12-ndt-3-145]) as well as in asymptomatic *parkin* mutation carriers ([@b73-ndt-3-145]), and in subjects with olfactory dysfunction ([@b67-ndt-3-145]). Thus transcranial sonography is a potential diagnostic tool in PD. It is attractive because it is a non-invasive, low risk test. However, more research needs to be performed to better determine if it is useful in the setting of diagnostic ambiguity early in the course of parkinsonism. Similarly, it remains to be established how well transcranial sonography performs in distinguishing PD and atypical parkinsonian syndromes, MSA in particular, and if it can be reliably used by multiple raters throughout the movement disorders centers.

Blood tests
-----------

PD is thought to be due, at least in part, to oxidative stress ([@b40-ndt-3-145]), and considerable effort has been spent in the search of a marker of this process. For example, patients with PD show a selective reduction in mitochondrial complex I in the substantia nigra ([@b64-ndt-3-145]), as well as in their platelets ([@b54-ndt-3-145]). The concentrations of several other potential markers of oxidative stress have been measured in the blood, such as malondialdehyde, superoxide radicals ([@b39-ndt-3-145]), the coenzyme Q10 redox ratio ([@b32-ndt-3-145]), 8-hydroxy-2′-deoxyguanosine from oxidized DNA, and 8-hydroxyguanosine from RNA oxidation ([@b41-ndt-3-145]; [@b3-ndt-3-145]). The levels tend to be abnormal in PD compared with control groups, providing valuable insight into the nature of oxidative stress, but none is sufficiently robust to be useful as a diagnostic marker of the disease process in the clinical practice. A similar situation exists if instead the levels of protective enzymes systems are compared, such as glutathione reductase, or copper and zinc superoxide dismutase ([@b39-ndt-3-145]).

An alternative approach may arise from studies dealing with peripheral dopamine system in PD. Studies on peripheral blood mononuclear cells have shown the reduction of intracellular dopamine concentrations ([@b20-ndt-3-145]), and tyrosine hydroxylase and dopamine transporter immunoreactivities ([@b20-ndt-3-145]; [@b21-ndt-3-145]). There is also evidence on the modulation of the expression of dopamine receptor mRNAs in the same cells ([@b50-ndt-3-145]; [@b6-ndt-3-145]). Although these findings are very promising, further studies are necessary before considering such methods useful for the differential diagnosis of PD as well as for the identification of at risk subjects.
